Suppr超能文献

北美接触性皮炎小组斑贴试验结果:2019 - 2020年

North American Contact Dermatitis Group Patch Test Results: 2019-2020.

作者信息

DeKoven Joel G, Warshaw Erin M, Reeder Margo J, Atwater Amber R, Silverberg Jonathan I, Belsito Donald V, Sasseville Denis, Zug Kathryn A, Taylor James S, Pratt Melanie D, Maibach Howard I, Fowler Joseph F, Adler Brandon L, Houle Marie-Claude, Mowad Christen M, Botto Nina, Yu JiaDe, Dunnick Cory A

机构信息

From the *Division of Dermatology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.

Division of Occupational Health, Unity Health Toronto, St. Michael's Hospital, Toronto, Canada.

出版信息

Dermatitis. 2023 Mar-Apr;34(2):90-104. doi: 10.1089/derm.2022.29017.jdk. Epub 2023 Jan 19.

Abstract

Patch testing is an important diagnostic tool for assessment of allergic contact dermatitis (ACD). This study documents the North American Contact Dermatitis Group (NACDG) patch testing results from January 1, 2019, to December 31, 2020. At 13 centers in North America, patients were tested in a standardized manner with a screening series of 80 allergens, and, as indicated, supplemental allergens. Overall, 4121 patients were tested; 2871 (69.7%) had at least 1 positive/allergic patch test reaction and 2095 patients (51.2%) had a primary diagnosis of ACD. The most commonly positive allergens were nickel (18.2%), methylisothiazolinone (MI) (13.8%), fragrance mix (FM) I (12.8%), hydroperoxides of linalool (HPL) (11.1%), and benzisothiazolinone (BIT) (10.4%). Compared with that of 2017-2018, prevalence of top 20 allergens statistically increased for FM I, HPL, BIT, propolis, and hydroperoxides of limonene (3.5%). For the first time, MI positivity did not increase between reporting periods. Approximately one-fifth of patients (20.3%) had ≥1 clinically relevant reaction(s) to allergens/substances not on the NACDG series. The epidemic of MI contact allergy in North America may have reached a plateau. Patch testing using a robust screening series, and supplemental allergens as indicated, is necessary for comprehensive evaluation of ACD.

摘要

斑贴试验是评估过敏性接触性皮炎(ACD)的重要诊断工具。本研究记录了2019年1月1日至2020年12月31日北美接触性皮炎组(NACDG)的斑贴试验结果。在北美的13个中心,对患者进行了标准化测试,使用包含80种变应原的筛查系列,以及根据需要使用的补充变应原。总体而言,共对4121例患者进行了测试;2871例(69.7%)至少有1次阳性/过敏斑贴试验反应,2095例患者(51.2%)的初步诊断为ACD。最常见的阳性变应原是镍(18.2%)、甲基异噻唑啉酮(MI)(13.8%)、香料混合物(FM)I(12.8%)、芳樟醇氢过氧化物(HPL)(11.1%)和苯并异噻唑啉酮(BIT)(10.4%)。与2017 - 2018年相比,FM I、HPL、BIT、蜂胶和柠檬烯氢过氧化物(3.5%)这前20种变应原的患病率在统计学上有所增加。MI阳性率在各报告期之间首次没有增加。约五分之一的患者(20.3%)对NACDG系列以外的变应原/物质有≥1次临床相关反应。北美MI接触性过敏的流行可能已达到平稳期。使用强大的筛查系列以及根据需要使用补充变应原进行斑贴试验,对于全面评估ACD是必要的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验